DC
SGMO

Diametric Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Diametric Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$87.3K Sell
353,477
-41,855
-11% -$16.7K 0.02% 427
2025
Q4 		$166K Buy
395,332
+36,324
+10% +$19.3K 0.04% 355
2025
Q3 		$242K Buy
+359,008
New +$194K 0.09% 279

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Diametric Capital's SGMO Position: Q1 2026 in Review

Diametric Capital reduced its SANGAMO THERAPEUTICS INC (SGMO) stake by 11% in Q1 2026, selling an estimated $16.7K and leaving 353,477 shares worth $87.3K. The position accounts for 0.02% of the portfolio, ranked #427.

Diametric Capital first reported a position in SGMO in Q3 2025 and has held it in 3 quarters since. The position peaked at $242K in Q3 2025. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Diametric Capital held 353,477 shares of SANGAMO THERAPEUTICS INC worth $87.3K as of Q1 2026.
  • Diametric Capital sold 41,855 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $16.7K.
  • SANGAMO THERAPEUTICS INC made up 0.02% of Diametric Capital's portfolio in Q1 2026, its #427 holding.
  • Diametric Capital first reported a position in SANGAMO THERAPEUTICS INC in Q3 2025 and has held it in 3 quarters since.
  • Diametric Capital's SANGAMO THERAPEUTICS INC position peaked at $242K in Q3 2025.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Diametric Capital's 13F filing for Q1 2026, filed 15 May 2026.